Programmed Cell Death-1 (PD-1) is a transmembrane immune checkpoint that normally blocks T cell activation; anti-PD-1 monoclonal antibodies that abrogate PD-1 and enhance T cell effector function immune checkpoint inhibitors (ICIs) have been shown to improve overall survival (OS) in several tumor types [3]. This evidence concerns the gene PDCD1 and neoplasm.